PULMOZYME® (dornase alfa) is a recombinant DNase enzyme formulated for inhalation. It works by enzymatically cleaving DNA in the sputum that accumulates in the airways of CF patients, thereby reducing the viscosity and elasticity of the mucus. This action helps to improve lung function and reduce the frequency of pulmonary exacerbations, significantly benefiting individuals with cystic fibrosis who suffer from chronic respiratory issues. The drug is administered using a nebulizer, with a typical dosage of 2.5 mg per day, although some patients may benefit from a higher frequency of administration (twice daily).

PULMOZYME® is a key component of cystic fibrosis therapy but should be used alongside other standard treatments like bronchodilators and antibiotics, as part of an individualized care regimen. It has been demonstrated in clinical trials to reduce pulmonary complications and improve respiratory outcomes in CF patients, making it an essential tool in the long-term management of the disease. However, proper administration and adherence to dosage instructions are critical to achieving the desired therapeutic outcomes.